Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma

被引：1

作者：

Ujjani, Chaitra ^{[1
]}

Cheson, Bruce D. ^{[1
]}

机构：

[1] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2010年 / 10卷 / 09期

关键词：

alkylating agent; antimetabolite; chemotherapy; chronic lymphocytic leukemia; non-Hodgkin's lymphoma; treanda; MULTICENTER PHASE-II; INDOLENT B-CELL; MANTLE CELL; PLUS RITUXIMAB; REFRACTORY INDOLENT; TRIAL; TOXICITY; BENDAMUSTINE/MITOXANTRONE/RITUXIMAB; CHEMOTHERAPY; FLUDARABINE;

D O I：

10.1586/ERA.10.116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bendamustine (Treanda (R); Pharmachemie BV, The Netherlands for Cephalon, Inc., PA, USA) is a unique cytotoxic agent with both alkylating and antimetabolite properties. A growing body of evidence demonstrates its efficacy in a number of hematologic malignancies, and as such, it has been US FDA approved for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma that has not responded to, or progressed within 6 months of, a rituximab-based regimen. Bendamustine has efficacy both as a single agent as well as in combination with other chemotherapeutics and immunotherapeutics. Here, we will discuss in the detail the molecular properties, clinical efficacy and safety profile of bendamustine.

引用

页码：1353 / 1365

页数：13

共 50 条

[31] EXPERIENCE OF A CENTER IN THE USE OF BENDAMUSTINE IN THE TREATMENT OF CHRONIC LYMPHATIC LEUKEMIA AND INDOLENT NON-HODGKIN LYMPHOMA
Elorza Begona, Navas
Nura, Jahangosha
Gil Sara, Nistal
Uson Concha, Alaez
HAEMATOLOGICA, 2016, 101 : 203 - 203
[32] Chronic lymphocytic leukemia supervening in non-Hodgkin's lymphoma (diffuse, mixed-cell type)
Yasuda, N
Ohmori, S
Usui, T
AMERICAN JOURNAL OF HEMATOLOGY, 1997, 55 (01) : 52 - 53
[33] Primary renal non-Hodgkin's lymphoma (NHL) and glomerulonephritis in NHL and chronic lymphocytic leukemia (CLL).
Da'as, N
Polliack, A
Ben-Yehuda, D
BLOOD, 1999, 94 (10) : 244B - 244B
[34] Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility
James, Elizabeth
Trautman, Holly
Thompson, Stephen
Ribalov, Rinat
Choudhry, Azhar
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 201 - 211
[35] NON-HODGKIN MALIGNANT-LYMPHOMA IN THE NAILS IN THE COURSE OF A CHRONIC LYMPHOCYTIC-LEUKEMIA
PEDERSEN, LM
NORDIN, H
NIELSEN, H
LISSE, I
ACTA DERMATO-VENEREOLOGICA, 1992, 72 (04) : 277 - 278
[36] Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Cerhan, JR
Vachon, CM
Habermann, TM
Ansell, SM
Janney, CA
Zheng, W
Sellers, TA
Potter, JD
Folsom, AR
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 153 (11) : S121 - S121
[37] New hope for bendamustine in the treatment of non-Hodgkin's lymphoma
Wraight, Sophie
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (04) : 295 - 295
[38] Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: Importance of immunocytochemistry
Gopal, AK
Schuetze, SH
Maloney, DG
Weiden, PL
BLOOD, 1999, 94 (07) : 2537 - 2537
[39] Bendamustine in chronic lymphocytic leukemia and refractory lymphoma
Rummel, Mathias J.
SEMINARS IN HEMATOLOGY, 2008, 45 (03) : S7 - S10
[40] Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey
Baer, William H., II
Maini, Archana
Jacobs, Ira
PHARMACEUTICALS, 2014, 7 (05): : 530 - 544

← 1 2 3 4 5 →